Related Experiment Videos
Soft agar clonogenic assay for primary human renal carcinoma: in vitro chemotherapeutic drug sensitivity testing
Abstract:
Dispersed tumor cells from primary human renal adenocarcinomas showed typical clonogenic growth in soft agar in seven of 31 instances. In vitro chemotherapy sensitivity testing was performed successfully for five of the seven clonogenic tumors. Extensive inherent resistance to the cytotoxic effects of many standard and experimental chemotherapeutic agents were observed. Occasionally, a single drug showed marked cytotoxicity. Similar results were obtained with soft agar clonogenic chemotherapeutic drug sensitivity assays performed on cells from human renal carcinoma xenografts. These in vitro results agree with clinical experience in the chemotherapy of advanced renal carcinoma. It remains to be determined if the sensitivity or resistance to chemotherapeutic drugs of human renal carcinomas noted in vitro reflects the characteristics of the tumors in vivo. Our results show that it is feasible to evaluate the soft agar assay as a method for selecting drugs for individual patients with renal carcinoma, a disease for which no chemotherapeutic treatment can be recommended at present.
Insights
This study found that most human renal carcinoma cells are resistant to chemotherapy. However, the soft agar assay may help identify effective drugs for individual patients with this difficult-to-treat cancer.
Area of Science:
- Oncology
- Cancer Research
- Pharmacology
Background:
- Advanced renal carcinoma (kidney cancer) has limited effective chemotherapy options.
- Tumor cell resistance to standard treatments is a significant clinical challenge.
Purpose of the Study:
- To evaluate the feasibility of using a soft agar assay for in vitro chemotherapy sensitivity testing of human renal adenocarcinomas.
- To assess the inherent drug resistance of primary and xenografted renal carcinoma cells.
Main Methods:
- Dispersed tumor cells from primary human renal adenocarcinomas were cultured in soft agar to assess clonogenic growth.
- Chemotherapy sensitivity assays were performed on clonogenic tumor cells.
- Similar assays were conducted on cells from human renal carcinoma xenografts.
Main Results:
- Seven of 31 primary human renal adenocarcinomas exhibited clonogenic growth in soft agar.
- In vitro chemotherapy sensitivity testing was successful for five of these tumors.
- Extensive inherent resistance to multiple chemotherapeutic agents was observed, with occasional drug-specific cytotoxicity.
Conclusions:
- The soft agar assay is a feasible method for evaluating chemotherapy sensitivity in renal carcinoma.
- In vitro findings of drug resistance align with clinical observations in advanced renal carcinoma.
- This assay may offer a personalized approach to selecting treatments for renal carcinoma patients.